AVDL

Avadel Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 70.6%
Negative

Neutral
GlobeNewsWire
2 days ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
16 days ago
Avadel: Mispriced Leader In Once-Nightly Sleep Therapies
Avadel Pharmaceuticals is deeply undervalued, with LUMRYZ and Valiloxybate offering $2B+ peak sales potential in sleep disorders. AVDL's once-at-bedtime Oxybate franchise is clinically superior, patent-protected, and poised to take share from Jazz Pharmaceuticals amid generic threats. Upcoming catalysts include a pivotal litigation outcome with Jazz, rapid patient growth, and pipeline progress, all supporting a rerating opportunity.
Avadel: Mispriced Leader In Once-Nightly Sleep Therapies
Neutral
GlobeNewsWire
29 days ago
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept.
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
Positive
Seeking Alpha
1 month ago
Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating
Avadel's stellar 2024 performance is driven by LUMRYZ's strong revenue growth, positive net income, and robust patient demand. The $20M global licensing deal for valiloxybate diversifies Avadel's pipeline, positioning it for long-term expansion in sleep medicine. Institutional investor interest and a favorable litigation outcome validate Avadel's business model and de-risk its growth trajectory.
Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating
Neutral
GlobeNewsWire
1 month ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
1 month ago
Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Thomas McHugh - Senior VP, Principal Financial & Accounting Officer and CFO Susan Rodriguez - Chief Operating Officer Gregory Divis - CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech Equity Research here at the firm.
Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16 posters at World Sleep 2025, taking place September 5-10, in Singapore.
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
– Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia –
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET. Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m.
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Positive
Zacks Investment Research
1 month ago
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?
The mean of analysts' price targets for Avadel (AVDL) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?